1. Home
  2. TEI vs NKTR Comparison

TEI vs NKTR Comparison

Compare TEI & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TEI
  • NKTR
  • Stock Information
  • Founded
  • TEI 1993
  • NKTR 1990
  • Country
  • TEI United States
  • NKTR United States
  • Employees
  • TEI N/A
  • NKTR N/A
  • Industry
  • TEI Finance Companies
  • NKTR Biotechnology: Pharmaceutical Preparations
  • Sector
  • TEI Finance
  • NKTR Health Care
  • Exchange
  • TEI Nasdaq
  • NKTR Nasdaq
  • Market Cap
  • TEI 242.3M
  • NKTR 247.9M
  • IPO Year
  • TEI N/A
  • NKTR 1994
  • Fundamental
  • Price
  • TEI $5.13
  • NKTR $0.94
  • Analyst Decision
  • TEI
  • NKTR Buy
  • Analyst Count
  • TEI 0
  • NKTR 3
  • Target Price
  • TEI N/A
  • NKTR $4.00
  • AVG Volume (30 Days)
  • TEI 142.4K
  • NKTR 2.0M
  • Earning Date
  • TEI 01-01-0001
  • NKTR 11-07-2024
  • Dividend Yield
  • TEI 10.51%
  • NKTR N/A
  • EPS Growth
  • TEI N/A
  • NKTR N/A
  • EPS
  • TEI N/A
  • NKTR N/A
  • Revenue
  • TEI N/A
  • NKTR $93,137,000.00
  • Revenue This Year
  • TEI N/A
  • NKTR $12.85
  • Revenue Next Year
  • TEI N/A
  • NKTR N/A
  • P/E Ratio
  • TEI N/A
  • NKTR N/A
  • Revenue Growth
  • TEI N/A
  • NKTR 5.53
  • 52 Week Low
  • TEI $4.35
  • NKTR $0.48
  • 52 Week High
  • TEI $5.39
  • NKTR $1.93
  • Technical
  • Relative Strength Index (RSI)
  • TEI 32.34
  • NKTR 37.44
  • Support Level
  • TEI $5.13
  • NKTR $0.88
  • Resistance Level
  • TEI $5.25
  • NKTR $1.04
  • Average True Range (ATR)
  • TEI 0.09
  • NKTR 0.06
  • MACD
  • TEI -0.01
  • NKTR 0.00
  • Stochastic Oscillator
  • TEI 5.37
  • NKTR 34.05

About TEI Templeton Emerging Markets Income Fund Inc.

Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Share on Social Networks: